These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 39284112)
1. CSF and Plasma Biomarkers in Patients With Iatrogenic Cerebral Amyloid Angiopathy. Pollaci G; Potenza A; Gorla G; Carrozzini T; Marinoni G; De Toma C; Canavero I; Rifino N; Boncoraglio GB; Difrancesco JC; Damavandi PT; Stanziano M; Erbetta A; Caroppo P; Di Fede G; Catania M; Zulueta A; Parati EA; Bersano A; Gatti L; Storti B Neurology; 2024 Oct; 103(8):e209828. PubMed ID: 39284112 [TBL] [Abstract][Full Text] [Related]
2. Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria. Renard D; Castelnovo G; Wacongne A; Le Floch A; Thouvenot E; Mas J; Gabelle A; Labauge P; Lehmann S J Neurol; 2012 Nov; 259(11):2429-33. PubMed ID: 22576334 [TBL] [Abstract][Full Text] [Related]
6. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis. Charidimou A; Friedrich JO; Greenberg SM; Viswanathan A Neurology; 2018 Feb; 90(9):e754-e762. PubMed ID: 29386280 [TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal Fluid Profile of Tau, Phosphorylated Tau, Aβ42, and Aβ40 in Probable Cerebral Amyloid Angiopathy. Grangeon L; Paquet C; Guey S; Zarea A; Martinaud O; Rotharmel M; Maltête D; Quillard-Muraine M; Nicolas G; Charbonnier C; Chabriat H; Wallon D J Alzheimers Dis; 2022; 87(2):791-802. PubMed ID: 35367960 [TBL] [Abstract][Full Text] [Related]
8. Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy. de Kort AM; Kuiperij HB; Jäkel L; Kersten I; Rasing I; van Etten ES; van Rooden S; van Osch MJP; Wermer MJH; Terwindt GM; Schreuder FHBM; Klijn CJM; Verbeek MM Alzheimers Res Ther; 2023 Jun; 15(1):102. PubMed ID: 37270536 [TBL] [Abstract][Full Text] [Related]
9. The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy. De Kort AM; Kaushik K; Kuiperij HB; Jäkel L; Li H; Tuladhar AM; Terwindt GM; Wermer MJH; Claassen JAHR; Klijn CJM; Verbeek MM; Kessels RPC; Schreuder FHBM Alzheimers Res Ther; 2024 May; 16(1):99. PubMed ID: 38704569 [TBL] [Abstract][Full Text] [Related]
10. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy. Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij HB; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326 [TBL] [Abstract][Full Text] [Related]
12. Cerebral Amyloid Angiopathy in Patients with Cognitive Impairment: Cerebrospinal Fluid Biomarkers. Rothenberg KG; Bekris L; Leverenz JB; Wu J; Lee J; Statsevych V; Ruggieri P; Jones SE Dement Geriatr Cogn Disord; 2024; 53(5):248-254. PubMed ID: 38889704 [TBL] [Abstract][Full Text] [Related]
13. Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers. Orduña Dolado A; Stomrud E; Ashton NJ; Nilsson J; Quijano-Rubio C; Jethwa A; Brum WS; Brinkmalm Westman A; Zetterberg H; Blennow K; Janelidze S; Hansson O Alzheimers Res Ther; 2024 Jun; 16(1):132. PubMed ID: 38909218 [TBL] [Abstract][Full Text] [Related]
14. β-Amyloid in CSF: Biomarker for preclinical cerebral amyloid angiopathy. van Etten ES; Verbeek MM; van der Grond J; Zielman R; van Rooden S; van Zwet EW; van Opstal AM; Haan J; Greenberg SM; van Buchem MA; Wermer MJ; Terwindt GM Neurology; 2017 Jan; 88(2):169-176. PubMed ID: 27903811 [TBL] [Abstract][Full Text] [Related]
15. Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer's Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms. Dakterzada F; Cipriani R; López-Ortega R; Arias A; Riba-Llena I; Ruiz-Julián M; Huerto R; Tahan N; Matute C; Capetillo-Zarate E; Piñol-Ripoll G Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731812 [TBL] [Abstract][Full Text] [Related]
16. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726 [TBL] [Abstract][Full Text] [Related]
17. Profiling amyloid-β peptides as biomarkers for cerebral amyloid angiopathy. van den Berg E; Kersten I; Brinkmalm G; Johansson K; de Kort AM; Klijn CJM; Schreuder FHBM; Gobom J; Stoops E; Portelius E; Gkanatsiou E; Zetterberg H; Blennow K; Kuiperij HB; Verbeek MM J Neurochem; 2024 Jul; 168(7):1254-1264. PubMed ID: 38362804 [TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal Fluid Biomarkers in Dementia Patients with Cerebral Amyloid Angiopathy. Li YF; Ge FF; Zhang Y; You H; Zhang ZX Chin Med Sci J; 2015 Sep; 30(3):170-3. PubMed ID: 26564416 [TBL] [Abstract][Full Text] [Related]
19. Reduced Levels of Cerebrospinal Fluid/Plasma Aβ40 as an Early Biomarker for Cerebral Amyloid Angiopathy in RTg-DI Rats. Zhu X; Xu F; Hoos MD; Lee H; Benveniste H; Nostrand WEV Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31906317 [TBL] [Abstract][Full Text] [Related]